➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

McKinsey
Boehringer Ingelheim
AstraZeneca
Baxter
Mallinckrodt
Moodys

Last Updated: July 5, 2020

DrugPatentWatch Database Preview

Claims for Patent: RE47301


Email this page to a colleague

» See Plans and Pricing

« Back to Dashboard

Summary for Patent: RE47301
Title:Process for preparing an A2A-adenosine receptor agonist and its polymorphs
Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A.sub.2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
Inventor(s): Zablocki; Jeff (Los Altos, CA), Elzein; Elfatih (Mountain House, CA), Seemayer; Robert (Belmont, CA), Lemons; Travis (Los Gatos, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:15/653,860
Patent Claims: 1. A pharmaceutical composition prepared from a crystalline monohydrate form of the compound (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide by adding at least one pharmaceutically acceptable carrier..].

.[.2. The pharmaceutical composition of claim 1, wherein the monohydrate is substantially free of 2-hydrazinoadenosine..].

.[.3. The pharmaceutical composition of claim 2, wherein the monohydrate is substantially free of other hydrates or amorphous form..].

.[.4. The pharmaceutical composition of claim 3, wherein the monohydrate has a purity of at least about 99.6%..].

.[.5. The pharmaceutical composition of claim 4, wherein the monohydrate exhibits an X-ray powder diffraction pattern having peaks at diffraction angle 2.theta. (.degree.) of about 6, about 9, about 11, about 13, about 14.5, about 16.5, and about 18 as measured by Cu-K.alpha.1 X-ray powder diffractometry..].

.Iadd.6. A pharmaceutical composition of an A.sub.2A-adenosine receptor agonist produced by a process comprising the following step: dissolving a crystalline monohydrate form of the compound (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide that is substantially free of 2-hydrazinoadenosine in a pharmaceutically acceptable carrier..Iaddend.

.Iadd.7. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate is substantially free of other hydrates or amorphous forms..Iaddend.

.Iadd.8. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate has a purity of at least about 99.6%..Iaddend.

.Iadd.9. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate exhibits an X-ray powder diffraction pattern having peaks at diffraction angle 2.theta. (.degree.) of about 6, about 9, about 11, about 13, about 14.5, about 16.5, and about 18 as measured by Cu-K.alpha.1 X-ray powder diffractometry..Iaddend.

.Iadd.10. The pharmaceutical composition of claim 6, wherein the crystalline monohydrate has an X-ray diffraction pattern as shown in FIG. 3..Iaddend.

.Iadd.11. A pharmaceutical composition comprising a crystalline monohydrate form of the compound (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide that is substantially free of 2-hydrazinoadenosine; and a pharmaceutically acceptable carrier..Iaddend.

.Iadd.12. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate is substantially free of other hydrates or amorphous forms..Iaddend.

.Iadd.13. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate has a purity of at least about 99.6%..Iaddend.

.Iadd.14. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate exhibits an X-ray powder diffraction pattern having peaks at diffraction angle 2.theta. (.degree.) of about 6, about 9, about 11, about 13, about 14.5, about 16.5, and about 18 as measured by Cu-K.alpha.1 X-ray powder diffractometry..Iaddend.

.Iadd.15. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate has an X-ray diffraction pattern as shown in FIG. 3..Iaddend.

.Iadd.16. The pharmaceutical composition of claim 11, wherein the crystalline monohydrate is dissolved in the pharmaceutically acceptable carrier..Iaddend.

.Iadd.17. A pharmaceutical composition comprising 99.6% pure (1-{9-[(4S,2R,3R,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-6-aminop- urin-2-yl}pyrazol-4-yl)-N-methylcarboxamide dissolved in a pharmaceutically acceptable carrier..Iaddend.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
Mallinckrodt
Dow
Colorcon
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.